Drug Profile
TBC 4521
Alternative Names: TBC4521Latest Information Update: 23 Aug 2006
Price :
$50
*
At a glance
- Originator Encysive Pharmaceuticals
- Class
- Mechanism of Action Caspase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Myocardial infarction; Stroke
Most Recent Events
- 23 Aug 2006 Discontinued - Preclinical for Myocardial infarction in USA (unspecified route)
- 23 Aug 2006 Discontinued - Preclinical for Stroke in USA (unspecified route)
- 06 Jun 2006 No development reported - Preclinical for Myocardial infarction in USA (unspecified route)